| Last Price | Today's Change | 52-Week Range | Trading Volume |
|---|---|---|---|
| 0.49 | 0.01 (+2.08%) | 0.302 - 1.10 | 131.6 thousand (Below Avg) |
Market data as of 3:52PM 05/21/13. Quotes are delayed by at least 15 min.
| Open | 0.50 |
|---|---|
| Previous Close | 0.48 |
| Day's Range | 0.48 - 0.50 |
| Market Cap | 43.2M |
| Avg Volume (10 Day) | 438.4K |
| Price/Earnings (Trailing 12 Mo.) | -- |
| Earnings Per Share (Trailing 12 Mo.) | |
| Dividend Yield | No Dividend |


These seven metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Performed well consistently? | Neutral |
|---|---|
| Avoids excess debt? | Neutral |
| Converting sales to profits? | Neutral |
| Shareholder's money handled rationally? | Neutral |
| Increased shareholder value? | Neutral |
| Consistently increased owner earnings? | Neutral |
| Sells at 25% discount to intrinsic value? | Neutral |


These eight metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Pays a cash dividend? | Neutral |
|---|---|
| Room to increase dividends? | Neutral |
| Increased earnings over time? | Neutral |
| Borrows within reasonable limits? | Neutral |
| Stock is undervalued? | Neutral |
| Have investors caught on? | Neutral |
| Has support of institutional investors? | Neutral |
| Has sufficient liquidity? | Neutral |
Transgenomic Announces Global Availability of CRC RAScan™ Mutation Detection Test for Use in Patients with Metastatic Colorectal Cancer to Help Identify Appropriate Treatment
Business Wire - Thursday 05/16/2013 7:00 AM ET
Transgenomic Reports First Quarter 2013 Financial Results
Business Wire - Wednesday 05/08/2013 4:00 PM ET
Reminder: Transgenomic to Hold First Quarter Financial Results Conference Call Today
Business Wire - Wednesday 05/08/2013 9:11 AM ET
Transgenomic Signs Collaboration Agreement with Amgen for Development of CE-IVD CRC RAScan™ Mutation Detection Tests for Patients with Metastatic Colorectal Cancer
Business Wire - Monday 05/06/2013 7:00 AM ET
Transgenomic to Hold First Quarter Financial Results Conference Call on May 8, 2013
Business Wire - Wednesday 05/01/2013 9:53 AM ET
| TBIO | Industry Range | |
|---|---|---|
| Revenue Growth (1yr) | -- | |
| Net Income Growth (1yr) | -- | |
| Total Debt/Equity | -- | |
| LT Debt/Equity | -- | |
| Earnings Yield | -- | |
| Price/Sales | -- |
| Company | Last | Change |
|---|
Data is delayed by at least 15 min.